Global Histone Methyltransferase Market Size, Share, and COVID-19 Impact Analysis, By Type (EZ, SET1, SET2, SMYD, SUV39, SUV4-20, and RIZ), By Application (Lung Cancer, Liver Cancer, Breast Cancer, and Others), and By Region (North America, Europe, Asia-Pacific, Latin America, Middle East, and Africa), Analysis and Forecast 2025 - 2035

Global Histone Methyltransferase Market Insights Forecasts to 2035

• The Global Histone Methyltransferase Market Size Was Estimated at USD 305.0 Million in 2024
• The Market Size is Expected to Grow at a CAGR of around 5.21% from 2025 to 2035
• The Worldwide Histone Methyltransferase Market Size is Expected to Reach USD 533.2 Million by 2035
• Asia Pacific is Expected to Grow the fastest during the forecast period.

The Global Histone Methyltransferase Market Size was worth around USD 305.0 Million in 2024 and is predicted to grow to around USD 533.2 Million by 2035 with a compound annual growth rate (CAGR) of 5.21% from 2025 to 2035. The growing prevalence of cancer, especially lung cancer, with an increasing application of histone methyltransferase as a biomarker for cancer diagnosis, is anticipated to drive the histone methyltransferase market worldwide.

Market Overview

The histone methyltransferase market refers to the commercial landscape surrounding enzymes catalysing the addition of methyl groups to histone proteins, which is a crucial epigenetic modification regulating gene expression. Histone methyltransferase (HMTs) are histone-modifying enzymes playing a vital role in epigenetics, specifically by catalysing the transfer of methyl groups to histone proteins. Increasing efforts towards research in genetics and epigenetics, underscoring the centrality of histone methyltransferase for modulating gene expression, are significantly driving the histone methyltransferase market. Furthermore, the shifting inclination towards personalized medicine for understanding the epigenetic landscape is contributing to driving the market growth for histone methyltransferase. Advancements in next-generation sequencing and bioinformatics for enabling more precise mapping of histone modifications are creating new market growth opportunities for histone methyltransferase.

Report Coverage

This research report categorizes the histone methyltransferase market based on various segments and regions, forecasts revenue growth, and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the histone methyltransferase market. Recent market developments and competitive strategies such as expansion, type launch, development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the histone methyltransferase market.

Driving Factors

The growing prevalence of cancer is responsible for driving the market demand as histone methyltransferase plays a crucial role in the development of new and more effective drugs, as a possible therapeutic target. In the year 2022, there were 20 million new cancer cases found, with 9.7 million deaths. Further, the growing application of histone methyltransferase as a biomarker for early cancer detection and diagnosis is anticipated to drive the market. In addition, the increasing research & development activities emphasizing cancer therapies, along with an increasing demand for personalized medicine, are contributing to propel the market growth.

Restraining Factors

Increased R&D costs, stringent regulatory requirements, supply chain disruptions, and geopolitical barriers are challenging the histone methyltransferase market. The complexity associated with understanding histone methyltransferase in various biological processes is challenging the market.

Market Segmentation

The histone methyltransferase market share is classified into type and application.

• The SMYD segment dominated the market with the largest share in 2024 and is projected to grow at a substantial CAGR during the forecast period.

Based on the type, the histone methyltransferase market is divided into EZ, SET1, SET2, SMYD, SUV39, SUV4-20, and RIZ. Among these, the SMYD segment dominated the market with the largest share in 2024 and is projected to grow at a substantial CAGR during the forecast period. SMYD protein, characterized by the presence of a SET domain and a MYND domain, is involved in various biological processes, like muscle development, cancer, and immune response. The potential of SMYD methyltransferase as a drug target with increasing research activity contributing to driving the market.

• The breast cancer segment accounted for the largest market share in 2024 and is anticipated to grow at a significant CAGR during the forecast period.

Based on the application, the histone methyltransferase market is divided into lung cancer, liver cancer, breast cancer, and others. Among these, the breast cancer segment accounted for the largest market share in 2024 and is anticipated to grow at a significant CAGR during the forecast period. Histone modifications are strongly associated with tumorigenesis and progression of breast cancer, maintaining genomic stability, transcription, DNA repair, and modulating chromatin in cancer cells. The growing prevalence of breast cancer, along with the approach towards personalized medicine, is propelling the histone methyltransferase market.

Regional Segment Analysis of the Histone Methyltransferase Market

• North America (U.S., Canada, Mexico) 
• Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
• Asia-Pacific (China, Japan, India, Rest of APAC)
• South America (Brazil and the Rest of South America) 
• The Middle East and Africa (UAE, South Africa, Rest of MEA)

North America is anticipated to hold the largest share of the histone methyltransferase market over the predicted timeframe.

North America is anticipated to hold the largest share of the histone methyltransferase market over the predicted timeframe. An increase in research activities associated with epigenetics and cancer therapies is driving the histone methyltransferase market. The high investment in cancer treatment, with an increased prevalence rate of cancer disease, is expected to propel the market demand for histone methyltransferase.  

Asia Pacific is expected to grow at a rapid CAGR in the histone methyltransferase market during the forecast period. The growing prevalence of cancer, including lung and liver cancer, along with upsurging awareness about cancer treatment, is driving the market growth of histone methyltransferase. An increasing technological development in the epigenetics field is contributing to propelling the market growth.

Europe is anticipated to hold a significant share of the histone methyltransferase market during the projected timeframe. Emergence of epigenetics for the study of changes in gene expression in cancer diagnosis, contributing to driving the histone methyltransferase market. An increasing application of histone methyltransferase as a biomarker in the diagnosis of cancer is propelling the market growth.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the histone methyltransferase market, along with a comparative evaluation primarily based on their type of offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes type development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Diagenode, Inc.
• Cell Signaling Technology, Inc.
• Cayman Chemical Company
• Constellation Pharmaceuticals
• CELLCENTRIC LIMITED
• Sequenom, Inc.
• Bellbrook Labs
• Merck KGaA
• Active motif, Inc.
• Thermo Fisher Scientific Inc.
• Epizyme, Inc.
• Sigma-Aldrich Corporation
• Ribomed Biotechnologies, Inc.
• Boehringer Ingelheim group
• Others

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting And Research Firm
• Venture capitalists
• Value-Added Resellers (VARs) 

Recent Development

• In September 2021, Boehringer Ingelheim announced that it acquired Abexxa Biologics, a developer of precision medicines for treating cancer.

• In March 2021, Hologic acquired molecular diagnostic assays and epigenetics products manufacturer Diagenode in a deal worth approximately $159m.

Market Segment

This study forecasts revenue at global, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the histone methyltransferase market based on the below-mentioned segments: 

Global Histone Methyltransferase Market, By Type

• EZ
• SET1
• SET2
• SMYD
• SUV39
• SUV4-20
• RIZ

Global Histone Methyltransferase Market, By Application

• Lung Cancer
• Liver Cancer
• Breast Cancer
• Others

Global Histone Methyltransferase Market, By Regional Analysis

• North America
  • US
  • Canada
  • Mexico
• Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Rest of Asia Pacific
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Middle East & Africa
  • UAE
  • Saudi Arabia
  • Qatar
  • South Africa
  • Rest of the Middle East & Africa